Evaluation of a Mainstream Model of Genetic Testing for Men With Prostate Cancer
Tahlia Scheinberg, Annabel Goodwin, Emilia Ip, Anthony Linton, Blossom Mak, David P Smith, Martin R Stockler, Madeleine C Strach, Ben Tran, Alison L Young, Alison Y Zhang, Kate L Mahon, Lisa G Horvath
JCO ONCOLOGY PRACTICE | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021
PURPOSE: To identify the approximately 12% with inherited cancer predisposition, all men with metastatic prostate cancer (mPC) should be offered germline genetic testing. This guides treatment choices and impacts cancer prevention in the family. Limited genetic services globally present a barrier to testing. This study tested a potential solution, "mainstreaming," where counseling and testing are performed by the patient's oncologist. PATIENTS AND METHODS: Men with mPC at three Australian sites were offered germline genetic testing at their medical oncology appointment. Panel testing (ATM, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, FANCA, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51D, and TP53)..View full abstract
Awarded by Cancer Institute NSW Program
Supported by Sydney Catalyst, University of Sydney, NSW (T.S.); Australia and Cancer Institute, NSW (T.S.); the Movember Foundation (K.L.M.); Prostate Cancer Foundation of Australia (K.L.M.); a fellowship grant from the Cancer Institute, NSW (E.I.); Cancer Institute NSW Program Grant No. CINSW 83; and the Australian Prostate Cancer Research Centre, NSW.